Synthesis and Anti‐Inflammatory Bowel Disease Activity of Pterostilbene Derivatives

Abstract

The aberrant activation of NLRP3 inflammasomes is intricately linked to various inflammatory diseases. In this study, we present the discovery and optimization of a series of NLRP3 inflammasome inhibitors based on the pterostilbene skeleton. All compounds underwent screening to evaluate their inhibitory effects on LPS/Nigericin‐induced IL‐1β secretion and anti‐cellular pyroptosis. Most compounds exhibit good biological activity and cellular safety, with compound D20 showing the most prominent activity. Preliminary mechanism studies suggest that compound D20 may affect the assembly of NLRP3 inflammasomes by targeting the NLRP3 protein, thereby inhibiting the activation of NLRP3 inflammasomes. The in vivo anti‐inflammatory activity demonstrated significant therapeutic effect of compound D20 on DSS‐induced acute colitis model in mice. This work has important reference significance for the development of drugs targeting NLRP3 inflammasomes.